<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pulm Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Pulm Med</journal-id><journal-title-group><journal-title>BMC Pulmonary Medicine</journal-title></journal-title-group><issn pub-type="epub">1471-2466</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23590701</article-id><article-id pub-id-type="pmc">3637063</article-id><article-id pub-id-type="publisher-id">1471-2466-13-23</article-id><article-id pub-id-type="doi">10.1186/1471-2466-13-23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Oral intake of phenylbutyrate with or without vitamin D<sub>3</sub> upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Mily</surname><given-names>Akhirunnesa</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mily@icddrb.org</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A2"><name><surname>Rekha</surname><given-names>Rokeya Sultana</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>rokeya.sultana.rekha@ki.se</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Kamal</surname><given-names>S M Mostafa</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>ntrlnidch@yahoo.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Akhtar</surname><given-names>Evana</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>evana@icddrb.org</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Sarker</surname><given-names>Protim</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>protim@icddrb.org</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Rahim</surname><given-names>Zeaur</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>zeaur@icddrb.org</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Gudmundsson</surname><given-names>Gudmundur H</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>ghrafn@hi.is</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Agerberth</surname><given-names>Birgitta</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>birgitta.agerberth@ki.se</email></contrib><contrib contrib-type="author" corresp="yes" id="A9"><name><surname>Raqib</surname><given-names>Rubhana</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>rubhana@icddrb.org</email></contrib></contrib-group><aff id="I1"><label>1</label>International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Mohakhali, Dhaka, 1212, Bangladesh</aff><aff id="I2"><label>2</label>Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 17177, Sweden</aff><aff id="I3"><label>3</label>National Institute of the Diseases of the Chest and Hospital, Mohakhali, Dhaka, 1212, Bangladesh</aff><aff id="I4"><label>4</label>Institute of Biology, University of Iceland, Reykjavik, 101, Iceland</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>16</day><month>4</month><year>2013</year></pub-date><volume>13</volume><fpage>23</fpage><lpage>23</lpage><history><date date-type="received"><day>23</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>28</day><month>3</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Mily et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Mily et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2466/13/23"/><abstract><sec><title>Background</title><p>We earlier showed that 4-phenylbutyrate (PB) can induce cathelicidin LL-37 expression synergistically with 1,25-dihydroxyvitamin D<sub>3</sub> in a lung epithelial cell line. We aimed to evaluate a therapeutic dose of PB alone or in combination with vitamin D<sub>3</sub> for induction of LL-37 expression in immune cells and enhancement of antimycobacterial activity in monocyte-derived macrophages (MDM).</p></sec><sec><title>Methods</title><p>Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250&#x000a0;mg (Group-I), 500&#x000a0;mg (Group-II) or 1000&#x000a0;mg (Group-III)] twice daily (b.d.) together with vitamin D<sub>3</sub> {5000&#x000a0;IU once daily (o.d.)}, PB (500&#x000a0;mg b.d.) (Group-IV) or vitamin D<sub>3</sub> (5000&#x000a0;IU o.d.) (Group-V), given orally for 4&#x000a0;days. Blood was collected on day-0, day-4 and day-8; plasma was separated, peripheral blood mononuclear cells (PBMC), non-adherent lymphocytes (NAL) and MDM were cultured. LL-37 transcript in cells and peptide concentrations in supernatant were determined by qPCR and ELISA, respectively. In plasma, 25-hydorxyvitamin D<sub>3</sub> levels were determined by ELISA. MDM-mediated killing of <italic>Mycobacterium tuberculosis (Mtb)</italic> (H37Rv) was performed by conventional culture method.</p></sec><sec><title>Results</title><p>MDM from Group-II had increased concentration of LL-37 peptide and transcript at day-4, while Group-I showed increased transcript at day-4 and day-8 compared to day-0 (p&#x02009;&#x0003c;&#x02009;0.05). Both Group-I and -II exhibited higher levels of transcript on day-4 compared to Group-III and Group-V (p&#x02009;&#x0003c;&#x02009;0.035). Increased induction of peptide was observed in lymphocytes from Group-II on day-4 compared to Group-I and Group-IV (p&#x02009;&#x0003c;&#x02009;0.05), while Group-IV showed increased levels on day-8 compared to Group-I and Group-III (p&#x02009;&#x0003c;&#x02009;0.04). Intracellular killing of <italic>Mtb</italic> on day-4 was significantly increased compared to day-0 in Group-I, -II and -V (p&#x02009;&#x0003c;&#x02009;0.05).</p></sec><sec><title>Conclusion</title><p>The results demonstrate that 500&#x000a0;mg b.d. PB with 5000&#x000a0;IU o.d. vitamin D<sub>3</sub> is the optimal dose for the induction of LL-37 in macrophages and lymphocytes and intracellular killing of <italic>Mtb</italic> by macrophages. Hence, this dose has potential application in the treatment of TB and is now being used in a clinical trial of adults with active pulmonary TB (NCT01580007).</p></sec></abstract><kwd-group><kwd>Innate immunity</kwd><kwd>Antimicrobial peptides</kwd><kwd>Monocyte derived macrophages</kwd><kwd><italic>Mycobacterium</italic></kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Tuberculosis (TB), caused by <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>), is a predominant public health problem worldwide and responsible for about 3 million deaths annually [<xref ref-type="bibr" rid="B1">1</xref>]. The prevalence of TB is increasing due to the spread of antibiotic-resistant strains of <italic>Mtb</italic>[<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. The deleterious consequences of co-infection with HIV is the emergence of XDR (extremely drug resistance) cases in Africa and other countries in recent years [<xref ref-type="bibr" rid="B4">4</xref>]. Advances in anti-tuberculous therapies and alternative treatment strategies are urgently required for the treatment of TB patients and exposed individuals at high risk of developing TB [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Antimicrobial peptides (AMPs) are important effectors of the innate defense system [<xref ref-type="bibr" rid="B7">7</xref>]. AMPs can limit growth and virulence properties of microbes directly or indirectly by enhancing the host immune system. Induction of endogenous AMP expression by administration of extrinsic compounds may be an attractive approach for alternative therapy in combating infectious diseases. Cathelicidins [<xref ref-type="bibr" rid="B8">8</xref>] and Defensins [<xref ref-type="bibr" rid="B9">9</xref>] and are major classes of AMPs, in mammals LL-37 is the only human cathelicidin and is expressed by both circulating white blood cells and epithelial surfaces including lungs [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>The active form of vitamin D<sub>3</sub> was shown to regulate the production of AMPs, i.e. cathelicidin LL-37, which plays an important role in the innate immune defense against infections including TB [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. These studies have encouraged many investigators to initiate vitamin D trials in TB patients with renewed enthusiasm [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>] (<ext-link ext-link-type="uri" xlink:href="http://NCT01130311">http://NCT01130311</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://NCT00507000">http://NCT00507000</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://NCT00366470">http://NCT00366470</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://NCT00677339">http://NCT00677339</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://NCT00918086">http://NCT00918086</ext-link>). In a systemic review and meta-analysis of observational studies, evidence of an association with vitamin D<sub>3</sub> deficiency and active TB was demonstrated [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>Our group has earlier shown that cathelicidin is downregulated in the mucosal epithelia during acute diarrhea [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>] and in infection with <italic>Neisseria gonorrhea</italic>[<xref ref-type="bibr" rid="B19">19</xref>]. We showed that the downregulation of the rabbit cathelicidin (CAP-18) in the large intestine can be counteracted by oral treatment with sodium butyrate, a short chain fatty acid and phenylbutyrate (PB), an analogue of butyrate in experimental model of shigellosis [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. PB further counteracted the downregulation of CAP-18 in the lung and tracheal epithelia through systemic effects [<xref ref-type="bibr" rid="B20">20</xref>]. We further demonstrated that PB can induce LL-37 expression synergistically with 1,25-dihydroxyvitamin D<sub>3</sub> at both protein and mRNA levels in a lung epithelial cell line [<xref ref-type="bibr" rid="B21">21</xref>]. It is thus likely that oral supplementation with PB will boost innate immunity in the lung mucosa by increasing expression of innate defense proteins. A dose of PB corresponding to that used for rabbits [<xref ref-type="bibr" rid="B20">20</xref>] for induction of cathelicidin was calculated by allometric scaling for use in adults. The calculations suggested that an effective dose for a 60&#x000a0;kg human would be approximately 600&#x000a0;mg of PB twice daily.</p><p>Our aim in this study was to determine the optimal dose of PB with or without vitamin D<sub>3</sub> in adults for induction of LL-37 in immune cells and increase in functional capacity of macrophages in killing of <italic>Mtb</italic>. Thus, healthy adult volunteers were treated with different doses of PB and in combination with a defined concentration of vitamin D<sub>3</sub>.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study design</title><p>Healthy participants (age range 18 to 55&#x000a0;yrs; n&#x02009;=&#x02009;15) working at International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) and National Institute of the Diseases of the Chest and Hospital (NIDCH), Dhaka, Bangladesh were recruited in this study. The study was approved by the Ethical Review Committee of icddr,b. Informed consent was obtained from the participants after explaining the nature and purpose of the study. Individuals were excluded if they had symptoms or clinical signs of infection, e.g. fever or diarrhea within the last 2&#x02013;3&#x000a0;months, if taking corticosteroids, diuretics, or supplementary vitamin D<sub>3</sub> (either alone or as part of a multivitamin preparation). The volunteers were asked to abstain from taking any vitamins or supplements for at least two weeks prior to and during the study period. There were five groups, each consisting of 3 participants. Groups-I, -II and -III received the following doses respectively: 250&#x000a0;mg, 500&#x000a0;mg or 1&#x000a0;g of PB b.d. plus 5000&#x000a0;IU vitamin D<sub>3</sub> o.d. for 4 consecutive days. Group-IV received 500&#x000a0;mg PB b.d. and Group-V received 5000&#x000a0;IU vitamin D<sub>3</sub> o.d. for 4 consecutive days. All healthy volunteers were followed for another 4&#x000a0;days after the treatment to monitor possible side effects. Four-phenylbutyrate (Tributyrate) and the placebo tablet were obtained from Fyrkl&#x000f6;vern Scandinavia AB, M&#x000f6;nster&#x000e5;s, Sweden; vitamin D<sub>3</sub> (Vigantol oil) and the placebo oil were obtained from Merck KGaA, Darmstadt, Germany. The healthy volunteer trial was conducted to determine an optimal dose for the clinical trial in TB patients (<ext-link ext-link-type="uri" xlink:href="http://NCT01580007">http://NCT01580007</ext-link>).</p></sec><sec><title>Blood collection and cell culture</title><p>Peripheral blood was collected at 3 time points <italic>(</italic>day-0, day-4 and day-8) from each participant (25&#x000a0;mL/individual). Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll-Hypaque density gradient centrifugation and plasma was collected and stored at &#x02212;20&#x000b0;C for later measurement of 25-hydroxyvitamin D<sub>3</sub>, calcium, (serum glutamate pyruvate transaminase (SGPT; liver function marker) and creatinine (kidney function marker). The PBMC pellet was washed and suspended in a culture medium containing 10% autologous plasma in RPMI-1640, 1% L-glutamine, 1% sodium pyruvate, 0.5% amphotericin B and 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA) and plated in two parallel 4-well tissue culture plates (NUNC, Roskilde, Denmark). One tissue culture plate was utilized for analyses of LL-37 peptide and transcript and the other plate was used for macrophage-mediated <italic>Mtb</italic> killing assay.</p><p>PBMCs were counted and incubated in culture plates for 3&#x000a0;days. Thereafter, supernatant containing the non-adherent cells (mostly lymphocytes, 80-90%) was removed, centrifuged to collect the clear supernatant which was the extracellular fluid (ECF) of PBMC. The non-adherent lymphocytes were treated with saponin for 10&#x000a0;minutes, centrifuged and supernatant collected as intracellular fluid (ICF) from lymphocytes. Supernatant and cell pellet were stored for further analysis. The remaining adherent cells in the culture plate were MDM, which were harvested and treated with saponin. After centrifugation, supernatant (ICF) and cells were stored until further analysis. RNALater (Qiagen GmbH, Hilden, Germany) was added to the cell pellet for RNA extraction. In another experiment, one part of PBMC was stimulated ex vivo with Bacille Calmette-Guerin, (BCG, 10&#x000a0;&#x003bc;g/mL: Japan BCG Laboratory, Tokyo, Japan) for 3&#x000a0;days, supernatant containing the non-adherent cells was removed, centrifuged to collect the clear supernatant which was the ECF of BCG stimulated PBMC.</p></sec><sec><title>Vitamin D<sub>3</sub>, calcium, albumin, SGPT and creatinine in plasma</title><p>In plasma, 25-hydroxyvitamin D<sub>3</sub> was measured by a commercial ELISA kit (IDS, Fountain Hills, Arizona, USA) that determines 25-hydroxyvitamin D<sub>3</sub> (100%), 25-hydroxyvitamin D<sub>2</sub> (75%) and 24,25-dihydroxyvitamin D<sub>3</sub> (&#x02265;100%). Calcium, albumin and creatinine were assessed by Roche automated clinical chemistry analyzer, Hitachi 902. Serum glutamate-pyruvate transaminase (SGPT) was measured by Beckman-Coulter AU680 (Japan).</p></sec><sec><title>LL-37 ELISA</title><p>LL-37 levels in ICF of macrophage and lymphocyte lysates as well as in ECF of PBMC and BCG stimulated PBMC were measured by ELISA. Duplicate samples were tested and concentrations were calculated using a standard curve generated from synthetic LL-37 (Innovagen, Lund, Sweden). Brief procedure of ELISA is as follow. Polystyrene microtiter plates (Maxisorp by NUNC, Naperville, IL, USA) were coated with monoclonal anti-LL-37 [<xref ref-type="bibr" rid="B22">22</xref>] (5&#x000a0;&#x003bc;g/ml) in carbonate buffer (15&#x000a0;mM sodium carbonate, 35&#x000a0;mM sodium bicarbonate and 0.02% sodium azide [pH&#x000a0;9.6]) and incubated overnight at 4&#x000b0;C. After washing, non-specific binding was blocked with 0.1% gelatin in tris-buffered saline (pH&#x000a0;7.5) for 1&#x000a0;hour at RT. Standards and samples were then added and incubated overnight at 4&#x000b0;C. Biotinylated rabbit anti-LL-37 (1&#x000a0;&#x003bc;g/mL) (Innovagen) was added and incubated for 2&#x000a0;h at room temperature (RT), followed by the incubation with Streptavidin-alkaline phosphatase conjugate (Chemicon, Melbourne, Australia) for another 2&#x000a0;h at RT. Four-methylumbelliferyl phosphate was used as substrate (Molecular Probes, Europe BV, Leiden, The Netherlands) and fluorescence was measured at an excitation wavelength of 360&#x000a0;nm and emission wavelength of 450&#x000a0;nm.</p></sec><sec><title>Quantitative real time RT-PCR amplification of LL-37 mRNA</title><p>RNA was extracted from macrophages and lymphocytes utilizing RNeasy Mini kit as described by the manufacturer (Qiagen GmbH). cDNA was synthesized using Superscript III First-Strand Synthesis System (Invitrogen, Grand Island, NY, USA). The CAMP gene encoding transcript LL-37 relative to the housekeeping 18S rRNA was measured in triplicate from the cDNA samples by real-time quantitative RT-PCR using CFX96 Real-Time PCR Detection Systems (Bio-Rad,) and the 18&#x000a0;s rRNA&#x02013;housekeeping gene kit (Applied Biosystems, Foster City, CA, USA). The sequences of forward and reverse primers for LL-37 transcript were 5&#x02019;-TCACCAGAGGATTGTGACTTCAA-3&#x02019; and 5&#x02019;-TGAGGGTCACTGTCCCCATAC-3&#x02019;, respectively (Primer Express; Applied Biosystems). The results were analyzed by using the relative standard method [<xref ref-type="bibr" rid="B19">19</xref>].</p></sec><sec><title>Macrophage mediated killing of <italic>Mycobacterium tuberculosis</italic></title><p>MDM in the culture plates were infected with previously prepared log phased <italic>Mtb</italic> H37Rv strain (from Tuberculosis Research Center, Chennai, India) in culture medium without antibiotics [<xref ref-type="bibr" rid="B23">23</xref>]. Initially 3 different multiplicity of infection (MOI; 1:10; 1:25 and 1:50) were tested and the ratio of 1:25 was found to be the optimal MOI, resulting in a clear bacterial killing. After 2&#x000a0;hours of exposure the culture plates were washed 3 times with warm RPMI to remove the extracellular bacteria and the infected MDM were cultured for three additional days in a medium with autologous plasma and antibiotics (penicillin-streptomycin, amphotericin B) (Gibco). Thereafter, the cells were lysed with 0.3% saponin-PBS and vigorous pipetting to collect viable intracellular <italic>Mtb</italic>. The lysates were cultured on Middle Brook 7H11 agar medium supplemented with 10% Middle Brook OADC (oleic acid, albumin, dextrose and catalase) enrichment (Becton Dickinson, Sparks, MD, USA). Bacterial viability was calculated by counting colony forming units (CFU) on agar plates after 21&#x02013;28&#x000a0;days of culture at 37&#x000b0;C. Before initiation of any intervention, the day-0 MDM-mediated killing served as the control for all groups.</p></sec><sec><title>Statistical analysis</title><p>Statistical analyses were performed using SigmaStat 3.1 for Windows (Systat Software Inc., Point Richmond, CA, USA) and SPSS 17.0 for Windows (SPSS Inc, Chicago, Illinois, USA). Results were expressed as mean with standard deviation. Sex and age was matched for each group. Data distribution patterns were checked by using scatter plots, and normality and homogeneity of variances were checked by descriptive statistics. Two-way repeated measure ANOVA was performed when both the sphericity and normality of the data was met. When condition for sphericity was violated or normality of data failed, one Way Analysis of Variance (ANOVA) was performed followed by the Tukey multiple comparison test for between groups and within group variables. Kruskal-Wallis ANOVA on Ranks was performed when data was not normally distributed. Analysis of Co-variance was performed when data at entry level was significantly different. P-values&#x02009;&#x0003c;&#x02009;0.05 were considered significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Plasma levels of vitamin D<sub>3</sub> and calcium</title><p>The average of 25-hydroxyvitamin D<sub>3</sub> levels in plasma increased in all groups except for Group-IV (treated with only PB). However, the increase was not significant (Figure <xref ref-type="fig" rid="F1">1</xref>). Sex and age was matched for each group. Similarly, no changes were observed in albumin-adjusted calcium levels during the study period in any of the groups (data not shown).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Plasma 25-hydroxyvitamin D</bold><sub><bold>3 </bold></sub><bold>concentration in healthy adults before and after supplementation.</bold> Group-I: 250&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-II: 500&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-III: 1000&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-IV: 500&#x000a0;mg PB b.d.; Group-V: 5000&#x000a0;IU vitamin D<sub>3</sub> o.d. PB: Phenylbutyrate. b.d.: twice daily. o.d. : once daily. Data were analyzed by One-way ANOVA.</p></caption><graphic xlink:href="1471-2466-13-23-1"/></fig><p>SGPT level before treatment was normal in all healthy volunteers except for one male volunteer in Group-I, who had 66.49&#x000a0;IU/L that was above the normal upper range of 56&#x000a0;IU/L. However, the SGPT level (12.08&#x000a0;IU/L) declined on day-4 to normal level. None of the volunteers showed any increase in SGPT level after ingestion of PB alone or in combination with vitamin D<sub>3</sub> on day-4 or &#x02212;8 (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1).</p></sec><sec><title>Synergistic effects of PB and vitamin D<sub>3</sub> on LL-37 expression in macrophages</title><p>Significant differences in concentration of MDM derived LL-37 transcripts and peptides were observed within days. A significant increase in both peptide (p&#x02009;=&#x02009;0.05) and transcript (p&#x02009;=&#x02009;0.011) was noted in Group-II in day-4 compared to day-0 (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>). Group-I showed significantly higher levels of LL-37 transcript but not peptide at day-4 (p&#x02009;=&#x02009;0.015) and day-8 (p&#x02009;=&#x02009;0.042) compared to day-0. Group-IV showed a marginal increase in LL-37 transcript levels on day-4 compared to day-0 (p&#x02009;=&#x02009;0.07) (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Expression of LL-37 transcript in monocyte-derived macrophages from healthy adults before and after supplementation</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left" valign="top">&#x000a0;</th><th rowspan="2" align="left" valign="top">&#x000a0;</th><th colspan="3" align="left" valign="bottom"><bold>LL-37 transcript (copy no.)</bold><hr/></th></tr><tr><th align="left"><bold>Day-0</bold></th><th align="left"><bold>Day-4</bold></th><th align="left"><bold>Day-8</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Group-I<hr/></td><td align="left" valign="bottom">MDM<hr/></td><td align="left" valign="bottom">9.68&#x02009;&#x000b1;&#x02009;9.0<hr/></td><td align="left" valign="bottom">64.37&#x02009;&#x000b1;&#x02009;19.03<sup>a 1,2</sup><hr/></td><td align="left" valign="bottom">21.61&#x02009;&#x000b1;&#x02009;18.71<sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">Group-II<hr/></td><td align="left" valign="bottom">MDM<hr/></td><td align="left" valign="bottom">16.24&#x02009;&#x000b1;&#x02009;1.77<hr/></td><td align="left" valign="bottom">62.42&#x02009;&#x000b1;&#x02009;19.56<sup>c 3,4</sup><hr/></td><td align="left" valign="bottom">38.25&#x02009;&#x000b1;&#x02009;15.65<hr/></td></tr><tr><td align="left" valign="bottom">Group-III<hr/></td><td align="left" valign="bottom">MDM<hr/></td><td align="left" valign="bottom">10.94&#x02009;&#x000b1;&#x02009;2.01<hr/></td><td align="left" valign="bottom">10.40&#x02009;&#x000b1;&#x02009;16.19<hr/></td><td align="left" valign="bottom">41.05&#x02009;&#x000b1;&#x02009;52.30<hr/></td></tr><tr><td align="left" valign="bottom">Group-IV<hr/></td><td align="left" valign="bottom">MDM<hr/></td><td align="left" valign="bottom">8.71&#x02009;&#x000b1;&#x02009;4.64<hr/></td><td align="left" valign="bottom">33.87&#x02009;&#x000b1;&#x02009;16.76<hr/></td><td align="left" valign="bottom">13.42&#x02009;&#x000b1;&#x02009;9.57<hr/></td></tr><tr><td align="left">Group-V</td><td align="left">MDM</td><td align="left">10.13&#x02009;&#x000b1;&#x02009;5.41</td><td align="left">11.54&#x02009;&#x000b1;&#x02009;12.90</td><td align="left">8.74&#x02009;&#x000b1;&#x02009;6.27</td></tr></tbody></table><table-wrap-foot><p>Note: Group-I: 250&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-II: 500&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-III: 1000&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-IV: 500&#x000a0;mg PB b.d.; Group-V: 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.. Data expressed as Mean&#x02009;&#x000b1;&#x02009;Standard Deviation. One Way Analysis of Variance (ANOVA) method was used for statistical analysis. Differences are significant, when p&#x02009;&#x0003c;&#x02009;0.05. Difference between, <sup>a</sup>day-4 and day-0 within Group-I (p&#x02009;=&#x02009;0.01); <sup>b</sup>day-8 and day-0 within Group-I (p&#x02009;=&#x02009;0.04); <sup>c</sup>day-4 and day-0 within Group-II (p&#x02009;=&#x02009;0.01); <sup>1</sup>Group-I and -III within day-4 (p&#x02009;=&#x02009;0.02); <sup>2</sup>Group-I and -V within day-4 (p&#x02009;=&#x02009;0.034); <sup>3</sup>Group-II and -III within day-4 (p&#x02009;=&#x02009;0.031); <sup>4</sup>Group-II and -V within day-4 (p&#x02009;=&#x02009;0.035). <italic>PB</italic>, Phenylbutyrate; <italic>MDM</italic>, Monocyte-derived macrophages; <italic>b.d</italic>., Twice daily; <italic>o.d</italic>., Once daily.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Expression of LL-37 peptide in monocyte-derived macrophages from healthy adults before and after supplementation</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left" valign="top">&#x000a0;</th><th rowspan="2" align="left" valign="top">&#x000a0;</th><th colspan="3" align="left" valign="bottom"><bold>LL-37 level in ICF (ng/million cells)</bold><hr/></th></tr><tr><th align="left"><bold>Day-0</bold></th><th align="left"><bold>Day-4</bold></th><th align="left"><bold>Day-8</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Group-I<hr/></td><td align="left" valign="bottom">MDM<hr/></td><td align="left" valign="bottom">0.52&#x02009;&#x000b1;&#x02009;0.06<hr/></td><td align="left" valign="bottom">0.72&#x02009;&#x000b1;&#x02009;0.28<hr/></td><td align="left" valign="bottom">0.68&#x02009;&#x000b1;&#x02009;0.19<hr/></td></tr><tr><td align="left" valign="bottom">Group-II<hr/></td><td align="left" valign="bottom">MDM<hr/></td><td align="left" valign="bottom">0.33&#x02009;&#x000b1;&#x02009;0.02<hr/></td><td align="left" valign="bottom">1.22&#x02009;&#x000b1;&#x02009;0.49<sup>a 1</sup><hr/></td><td align="left" valign="bottom">0.36&#x02009;&#x000b1;&#x02009;0.05<hr/></td></tr><tr><td align="left" valign="bottom">Group-III<hr/></td><td align="left" valign="bottom">MDM<hr/></td><td align="left" valign="bottom">0.28&#x02009;&#x000b1;&#x02009;0.00<hr/></td><td align="left" valign="bottom">0.27&#x02009;&#x000b1;&#x02009;0.02<hr/></td><td align="left" valign="bottom">0.27&#x02009;&#x000b1;&#x02009;0.02<hr/></td></tr><tr><td align="left" valign="bottom">Group-IV<hr/></td><td align="left" valign="bottom">MDM<hr/></td><td align="left" valign="bottom">0.15&#x02009;&#x000b1;&#x02009;0.02<hr/></td><td align="left" valign="bottom">0.13&#x02009;&#x000b1;&#x02009;0.02<hr/></td><td align="left" valign="bottom">0.16&#x02009;&#x000b1;&#x02009;0.02<hr/></td></tr><tr><td align="left">Group-V</td><td align="left">MDM</td><td align="left">0.21&#x02009;&#x000b1;&#x02009;0.08</td><td align="left">0.20&#x02009;&#x000b1;&#x02009;0.05</td><td align="left">0.23&#x02009;&#x000b1;&#x02009;0.09</td></tr></tbody></table><table-wrap-foot><p>Note: Group-I: 250&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-II: 500&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-III: 1000&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-IV: 500&#x000a0;mg PB b.d.; Group-V: 5000&#x000a0;IU vitamin D<sub>3</sub> o.d. Data expressed as Mean&#x02009;&#x000b1;&#x02009;Standard Deviation. One Way Analysis of Variance (ANOVA) method was used for statistical analysis. Kruskal-Wallis ANOVA on Ranks was performed when the data was not normally distributed; analysis of Co-variance was performed when significant difference was found at entry level. Differences are significant, when p&#x02009;&#x0003c;&#x02009;0.05. Difference between, <sup>a</sup>day-4 and day-0 within Group-II (p&#x02009;=&#x02009;0.02); <sup>1</sup>Group-II and -III within day-4 (p&#x02009;=&#x02009;0.034). <italic>ICF</italic>, Intracellular fluid; <italic>PB</italic>, Phenylbutyrate; <italic>MDM</italic>, Monocyte-derived macrophages; <italic>b.d</italic>., Twice daily; <italic>o.d</italic>., Once daily.</p></table-wrap-foot></table-wrap><p>When comparing between groups, Group-I and Group-II exhibited significantly higher levels of LL-37 transcript on day-4 compared to Group-III (p&#x02009;=&#x02009;0.025 and p&#x02009;=&#x02009;0.03 respectively) and Group-V (p&#x02009;=&#x02009;0.03 and p&#x02009;=&#x02009;0.035 respectively) (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). Furthermore, Group-II showed higher levels of peptide compared to Group-IV (p&#x02009;=&#x02009;0.01) (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p></sec><sec><title>PB and vitamin D<sub>3</sub> induce LL-37 expression in lymphocytes</title><p>Lymphocyte-derived LL-37 transcript did not show any significant induction within days (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). However, LL-37 peptide induction on day-4 was significantly higher in Group-II compared to Group-I (p&#x02009;=&#x02009;0.03) and Group-IV (p&#x02009;=&#x02009;0.05) (Table&#x000a0;<xref ref-type="table" rid="T4">4</xref>). Group-IV showed increased production of peptide on day-8 compared to Group-III (p&#x02009;=&#x02009;0.03) and Group-I (p&#x02009;=&#x02009;0.04).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Expression of LL-37 transcript in non-adherent lymphocytes in healthy adults before and after supplementation</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="3" align="left" valign="bottom"><bold>LL-37 transcript (copy no.)</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="left">&#x000a0;</th><th align="left"><bold>Day-0</bold></th><th align="left"><bold>Day-4</bold></th><th align="left"><bold>Day-8</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Group-I<hr/></td><td align="left" valign="bottom">NAL<hr/></td><td align="left" valign="bottom">9.60&#x02009;&#x000b1;&#x02009;2.80<hr/></td><td align="left" valign="bottom">19.5&#x02009;&#x000b1;&#x02009;7.65<hr/></td><td align="left" valign="bottom">7.46&#x02009;&#x000b1;&#x02009;5.00<hr/></td></tr><tr><td align="left" valign="bottom">Group-II<hr/></td><td align="left" valign="bottom">NAL<hr/></td><td align="left" valign="bottom">29.57&#x02009;&#x000b1;&#x02009;6.17<hr/></td><td align="left" valign="bottom">54.43&#x02009;&#x000b1;&#x02009;16.48<hr/></td><td align="left" valign="bottom">38.25&#x02009;&#x000b1;&#x02009;20.66<hr/></td></tr><tr><td align="left" valign="bottom">Group-III<hr/></td><td align="left" valign="bottom">NAL<hr/></td><td align="left" valign="bottom">19.33&#x02009;&#x000b1;&#x02009;8.21<hr/></td><td align="left" valign="bottom">30.00&#x02009;&#x000b1;&#x02009;10.60<hr/></td><td align="left" valign="bottom">20.00&#x02009;&#x000b1;&#x02009;5.01<hr/></td></tr><tr><td align="left" valign="bottom">Group-IV<hr/></td><td align="left" valign="bottom">NAL<hr/></td><td align="left" valign="bottom">14.78&#x02009;&#x000b1;&#x02009;3.08<hr/></td><td align="left" valign="bottom">18.68&#x02009;&#x000b1;&#x02009;5.92<hr/></td><td align="left" valign="bottom">19.12&#x02009;&#x000b1;&#x02009;10.33<hr/></td></tr><tr><td align="left">Group-V</td><td align="left">NAL</td><td align="left">9.18&#x02009;&#x000b1;&#x02009;2.39</td><td align="left">23.30&#x02009;&#x000b1;&#x02009;14.58</td><td align="left">20.71&#x02009;&#x000b1;&#x02009;7.45</td></tr></tbody></table><table-wrap-foot><p>Note. Group-I: 250&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-II: 500&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-III: 1000&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-IV: 500&#x000a0;mg PB b.d.; Group-V: 5000&#x000a0;IU vitamin D<sub>3</sub> o.d. Data expressed as Mean&#x02009;&#x000b1;&#x02009;Standard Deviation. One Way Analysis of Variance (ANOVA) method was used. Analysis of Co-variance was performed when significant difference was found at entry level. <italic>PB</italic>, Phenylbutyrate; <italic>NAL</italic>, Non-adherent lymphocytes; <italic>b.d</italic>., Twice daily; <italic>o.d</italic>., Once daily.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Expression of LL-37 peptide in non-adherent lymphocytes in healthy adults before and after supplementation</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="3" align="left" valign="bottom"><bold>LL-37 level in ICF (ng/million cells)</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="left">&#x000a0;</th><th align="left"><bold>Day-0</bold></th><th align="left"><bold>Day-4</bold></th><th align="left"><bold>Day-8</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Group-I<hr/></td><td align="left" valign="bottom">NAL<hr/></td><td align="left" valign="bottom">0.24&#x02009;&#x000b1;&#x02009;0.07<hr/></td><td align="left" valign="bottom">0.23 &#x000b1;0.11<hr/></td><td align="left" valign="bottom">0.18&#x02009;&#x000b1;&#x02009;0.12<hr/></td></tr><tr><td align="left" valign="bottom">Group-II<hr/></td><td align="left" valign="bottom">NAL<hr/></td><td align="left" valign="bottom">0.28&#x02009;&#x000b1;&#x02009;0.04<hr/></td><td align="left" valign="bottom">0.49&#x02009;&#x000b1;&#x02009;0.16 <sup>1,2</sup><hr/></td><td align="left" valign="bottom">0.33&#x02009;&#x000b1;&#x02009;0.11<hr/></td></tr><tr><td align="left" valign="bottom">Group-III<hr/></td><td align="left" valign="bottom">NAL<hr/></td><td align="left" valign="bottom">0.31&#x02009;&#x000b1;&#x02009;0.11<hr/></td><td align="left" valign="bottom">0.25&#x02009;&#x000b1;&#x02009;0.02<hr/></td><td align="left" valign="bottom">0.17&#x02009;&#x000b1;&#x02009;0.06<hr/></td></tr><tr><td align="left" valign="bottom">Group-IV<hr/></td><td align="left" valign="bottom">NAL<hr/></td><td align="left" valign="bottom">0.27&#x02009;&#x000b1;&#x02009;0.14<hr/></td><td align="left" valign="bottom">0.21&#x02009;&#x000b1;&#x02009;0.02<hr/></td><td align="left" valign="bottom">0.68&#x02009;&#x000b1;&#x02009;0.32 <sup>3,4</sup><hr/></td></tr><tr><td align="left">Group-V</td><td align="left">NAL</td><td align="left">0.19&#x02009;&#x000b1;&#x02009;0.08</td><td align="left">0.37&#x02009;&#x000b1;&#x02009;0.07</td><td align="left">0.27&#x02009;&#x000b1;&#x02009;0.15</td></tr></tbody></table><table-wrap-foot><p>Note: Group-I: 250&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-II: 500&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-III: 1000&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-IV: 500&#x000a0;mg PB b.d.; Group-V: 5000&#x000a0;IU vitamin D<sub>3</sub> o.d. Data expressed as Mean&#x02009;&#x000b1;&#x02009;Standard Deviation. One Way Analysis of Variance (ANOVA) method was used for statistical analysis. Differences are significant, when p&#x02009;&#x0003c;&#x02009;0.05. Difference between, <sup>1</sup>Group-II and -I within day-4 (p&#x02009;=&#x02009;0.05); <sup>2</sup>Group-II and -IV within day-4 (p&#x02009;=&#x02009;0.03); <sup>3</sup>Group-IV and -I within day-8 (p&#x02009;=&#x02009;0.04); <sup>4</sup>Group-IV and-III within day-8 (p&#x02009;=&#x02009;0.036). <italic>ICF,</italic> Intracellular fluid; <italic>PB</italic>, Phenylbutyrate; <italic>NAL</italic>, Non-adherent lymphocytes; <italic>b.d.</italic>, Twice daily; <italic>o.d</italic>., Once daily.</p></table-wrap-foot></table-wrap></sec><sec><title>No effects of PB and vitamin D<sub>3</sub> on LL-37 expression in PBMC</title><p>There was no significant induction of LL-37 production in ECF of total PBMC within days or between groups. Stimulation of PBMC with live BCG also did not show any remarkable increase in LL-37 release in the ECF (0.53&#x02009;&#x000b1;&#x02009;0.17&#x000a0;ng/10<sup>6</sup> PBMC) compared to the ECF of unstimulated PBMC (0.50&#x02009;&#x000b1;&#x02009;0.17&#x000a0;ng/10<sup>6</sup> PBMC) (p&#x02009;=&#x02009;0.92).</p></sec><sec><title>PB and/or vitamin D<sub>3</sub> mediate enhanced killing of <italic>Mtb ex vivo</italic></title><p>Group-II demonstrated significantly higher intracellular killing of <italic>Mtb</italic> by MDM at day-4 (p&#x02009;=&#x02009;0.027) compared to day-0. Group-I and -V exhibited a significant increase in intracellular killing on day-4 (p&#x02009;&#x0003c;&#x02009;0.001 and p&#x02009;=&#x02009;0.019 respectively) and day-8 (p&#x02009;&#x0003c;&#x02009;0.001 and p&#x02009;=&#x02009;0.051 respectively) compared to day-0 (Figure <xref ref-type="fig" rid="F2">2</xref>). The other Groups did not show any increase in the killing activity of MDM (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Viable </bold><bold><italic>Mtb </italic></bold><bold>CFU count in Monocyte derived macrophages (MDM).</bold> MDM from different group of volunteers were incubated with <italic>Mtb</italic> H37Rv strain for 2&#x000a0;h, after that extracellular bacteria were removed and cultured for 3 days, cells were lysed and plated for variable colony (CFU) count. Group-I: 250&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-II: 500&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-III: 1000&#x000a0;mg PB b.d. + 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.; Group-IV: 500&#x000a0;mg PB b.d.; Group-V: 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.. PB: Phenylbutyrate. b.d.: twice daily. o.d. : once daily. The straight horizontal line indicates means. Data were analyzed by two-way (treatment and time) repeated measures ANOVA. * p&#x02009;&#x0003c;&#x02009;0.05, and *** p&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="1471-2466-13-23-2"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study we demonstrated that oral supplementation of healthy adult volunteers with 500&#x000a0;mg PB b.d. plus 5000&#x000a0;IU vitamin D<sub>3</sub> o.d. (Group-II) consistently induced LL-37 in both macrophages and lymphocytes, and also exhibited increased MDM derived intracellular killing of <italic>M. tuberculosis.</italic></p><p>In an animal model of shigellosis we have previously shown that <italic>Shigella</italic> infection causes downregulation of the rabbit cathelicidin CAP-18 in the epithelia of rectum, lung and trachea [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. Oral feeding of butyrate (0.14&#x000a0;mmol/dose) or PB (0.14&#x000a0;mmol/dose) up-regulates CAP-18 expression in the lung and rectal epithelia of these rabbits and reduces shedding of <italic>Shigella</italic> in stool [<xref ref-type="bibr" rid="B20">20</xref>]. We have also demonstrated that PB, induces the <italic>CAMP</italic> gene expression synergistically with 1,25-dihydroxyvitamin D<sub>3</sub> at both protein and mRNA levels in the VA10 lung epithelial cell line [<xref ref-type="bibr" rid="B21">21</xref>]. We have now further shown in humans, that oral intake of PB alone or in combination with vitamin D<sub>3</sub> can also induce LL-37 in immune cells. In this study, three potential doses of PB were selected for healthy adults. Group I (250&#x000a0;mg b.d. with 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.) showed significant increase in LL-37 transcript but not peptide in MDM; no changes in peptide or transcript was noted in NAL. Group-II (500&#x000a0;mg b.d. plus 5000&#x000a0;IU vitamin D<sub>3</sub> o.d.) showed increase in both peptide and transcript in MDM and peptide in NAL. In Group-III with the higher dose of PB (1&#x000a0;g b.d.) along with vitamin D<sub>3</sub> there was no increase in LL-37 transcript or peptide in cells after PB supplementation. Butyrate is known to inhibit RNA and protein synthesis at high concentrations [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. We may speculate that in a similar fashion PB at high doses is inhibitory to the expression of LL-37 both at transcriptional and translational levels. The dose of Group-II appears superior in inducing both peptide and mRNA concentrations in MDM and peptide in lymphocytes.</p><p>Various cell types including T lymphocytes are known to express LL-37 [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. However, to our knowledge this is the first study to report enhanced <italic>in vivo</italic> induction of LL-37 in lymphocytes after oral supplementation with PB alone or in combination with vitamin D<sub>3</sub>. This finding thus underscores the significance of PB therapy in TB infection since T cells play a major role in the host defense against tuberculosis [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>The present study showed that oral intake of vitamin D<sub>3</sub> (Group-V) alone or in combination with PB (Group-I and -II) exhibited a marked increase in intracellular killing of <italic>Mtb</italic>. Vitamin D<sub>3</sub>-induced LL-37 expression is an important factor in fighting TB [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Killing of <italic>Mtb</italic> by macrophages is directly correlated with <italic>CAMP</italic> gene expression encoding LL-37 and plasma levels of 25-hydroxyvitamin D<sub>3</sub>[<xref ref-type="bibr" rid="B12">12</xref>]. Furthermore, it was shown that activation of Toll-Like Receptor 2/1 in human macrophages up-regulated expression of the genes encoding vitamin D receptor and vitamin D-hydroxylase, leading to induction of LL-37 with subsequent killing of intracellular <italic>Mtb</italic>[<xref ref-type="bibr" rid="B11">11</xref>]. Recent studies have shown that human cathelicidin is a key mediator of 1,25-dihydroxyvitamin D<sub>3</sub>-induced autophagy and hence provide a mechanistic insight into the role of cathelicidin in combating <italic>Mtb</italic>[<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Interestingly, <italic>in vitro</italic> studies have shown that short chain fatty acids, butyrate and propionate can induce both apoptosis and autophagy [<xref ref-type="bibr" rid="B32">32</xref>]. PB is an analogue of butyrate and it is quite likely that PB in combination with Vitamin D<sub>3</sub> may also induce autophagy and LL-37 mediated killing of <italic>Mtb ex vivo</italic>.</p><p>The major limitation of this study is the small sample size and the short duration of the PB and vitamin D<sub>3</sub> supplementation. The lack of increase in plasma 25-hydroxyvitamin D<sub>3</sub> level after 4&#x000a0;days supplementation was not unexpected since 1&#x02013;2&#x000a0;months supplementation is needed to reach steady state vitamin D<sub>3</sub> levels.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In conclusion, oral combination dose of 500&#x000a0;mg PB b.d. with 5000&#x000a0;IU vitamin D<sub>3</sub> o.d. appears to be the optimum dose to induce both LL-37 peptide and transcript expression in functional immune cells as well as enhance intracellular <italic>Mtb</italic> killing in macrophages. The dose of 250&#x000a0;mg PB b.d. with 5000&#x000a0;IU vitamin D<sub>3</sub> o.d. also increased intracellular killing however it enhanced only LL-37 transcript levels (not peptide) in macrophages but not in lymphocytes. This pilot study has generated results for a potential dose in a clinical trial of adults with active pulmonary TB (<ext-link ext-link-type="uri" xlink:href="http://NCT01580007">http://NCT01580007</ext-link>).</p><sec><title>Ethical approval</title><p>The study was approved by the Ethical Review Committee of International Centre for Diarrheal Disease Research, Bangladesh (icddr,b).</p></sec></sec><sec><title>Abbreviations</title><p>AMPs: Antimicrobial peptides; b.d.: Twice daily; CFU: Colony forming units; ECF: Extracellular fluid; HDAC: Histone deacetylase; ICF: Intracellular fluid; MDM: Monocyte-derived macrophages; Mtb: <italic>Mycobacterium tuberculosis</italic>; o.d.: Once daily; PB: 4-Phenylbutyrate; PBMCs: Peripheral blood mononuclear cells; TB: Tuberculosis.</p></sec><sec><title>Competing interests</title><p>Birgitta Agerberth, Gudmundur H. Gudmundsson and Rubhana Raqib have a pending patent application for the use of phenylbutyrate to the treatment of infections. There is no financial arrangement between any of the authors.</p></sec><sec><title>Authors&#x02019; contributions</title><p>RR, BA contributed to the conception and design of the study; AM, RSR, EA and PS performed laboratory analysis, AM, RSR and RR performed the statistical analysis; AM, RSR and RR prepare the first draft of the manuscript. BA, GHG, ZR, SMMK and PS revised the manuscript. All authors read and approved the final version of the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2466/13/23/prepub">http://www.biomedcentral.com/1471-2466/13/23/prepub</ext-link></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1: Table 1</title><p>Serum glutamate-pyruvate transaminase and creatinine levels in healthy adults supplemented with phenylbutyrate and vitamin D3 alone or in combination in different doses.</p></caption><media xlink:href="1471-2466-13-23-S1.pdf"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgement</title><p>The study was supported by icddr,b, &#x02018;the Swedish Agency for Research Cooperation with Developing Countries (Sida/SAREC Agreement support; grant 384, SWE-2008-065)&#x02019;; &#x02018;The Swedish Research Council, (grant 58X-11217-14-3)&#x02019;; &#x02018;The Swedish Strategic Foundation (SSF)&#x02019;; Swedish Cancer Society; &#x02018;Karolinska Institutet&#x02019;; &#x02018;The Icelandic Centre for Research (RANNIS)&#x02019; and &#x02018;University of Iceland research fund&#x02019;. icddr,b acknowledges with gratitude the commitment of all donors&#x02019; to it&#x02019;s research efforts. GHG is a visiting scientist supported by &#x02018;The Wenner-Gren Foundations&#x02019;. We thank the volunteers for participating in this study.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>PE</given-names></name><name><surname>Moss</surname><given-names>AR</given-names></name><article-title>Tuberculosis: pathogenesis, protection, and control, epidemiology of tuberculosis</article-title><source>Epidemiol Tuberc</source><year>1994</year><volume>1</volume><fpage>47</fpage><lpage>60</lpage></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Parsons</surname><given-names>LM</given-names></name><name><surname>Driscoll</surname><given-names>JR</given-names></name><name><surname>Taber</surname><given-names>HW</given-names></name><name><surname>Salfinger</surname><given-names>M</given-names></name><article-title>Drug resistance in tuberculosis</article-title><source>Infect Dis Clin North Am</source><year>1997</year><volume>11</volume><issue>4</issue><fpage>905</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1016/S0891-5520(05)70397-4</pub-id><pub-id pub-id-type="pmid">9421707</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Bradford</surname><given-names>WZ</given-names></name><name><surname>Daley</surname><given-names>CL</given-names></name><article-title>Multiple drug-resistant tuberculosis</article-title><source>Infect Dis Clin North Am</source><year>1998</year><volume>12</volume><issue>1</issue><fpage>157</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/S0891-5520(05)70415-3</pub-id><pub-id pub-id-type="pmid">9494836</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Gandhi</surname><given-names>NR</given-names></name><name><surname>Shah</surname><given-names>NS</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name><name><surname>Vella</surname><given-names>V</given-names></name><name><surname>Moll</surname><given-names>AP</given-names></name><name><surname>Scott</surname><given-names>M</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name><name><surname>Marra</surname><given-names>C</given-names></name><name><surname>Lalloo</surname><given-names>UG</given-names></name><name><surname>Friedland</surname><given-names>GH</given-names></name><article-title>HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><issue>1</issue><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1164/rccm.200907-0989OC</pub-id><pub-id pub-id-type="pmid">19833824</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Wejse</surname><given-names>C</given-names></name><name><surname>Gomes</surname><given-names>VF</given-names></name><name><surname>Rabna</surname><given-names>P</given-names></name><name><surname>Gustafson</surname><given-names>P</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Lisse</surname><given-names>IM</given-names></name><name><surname>Andersen</surname><given-names>PL</given-names></name><name><surname>Glerup</surname><given-names>H</given-names></name><name><surname>Sodemann</surname><given-names>M</given-names></name><article-title>Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>179</volume><issue>9</issue><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1164/rccm.200804-567OC</pub-id><pub-id pub-id-type="pmid">19179490</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Martins</surname><given-names>M</given-names></name><article-title>Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K&#x02009;+&#x02009;transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)&#x02013;a novel, patentable approach to limit the emergence of XDR-TB</article-title><source>Recent Pat Antiinfect Drug Discov</source><year>2011</year><volume>6</volume><issue>2</issue><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.2174/157489111796064524</pub-id><pub-id pub-id-type="pmid">21517742</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Zasloff</surname><given-names>M</given-names></name><article-title>Antimicrobial peptides of multicellular organisms</article-title><source>Nature</source><year>2002</year><volume>415</volume><issue>6870</issue><fpage>389</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1038/415389a</pub-id><pub-id pub-id-type="pmid">11807545</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Zaiou</surname><given-names>M</given-names></name><name><surname>Gallo</surname><given-names>RL</given-names></name><article-title>Cathelicidins, essential gene-encoded mammalian antibiotics</article-title><source>J Mol Med (Berl)</source><year>2002</year><volume>80</volume><issue>9</issue><fpage>549</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1007/s00109-002-0350-6</pub-id><pub-id pub-id-type="pmid">12226737</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Ganz</surname><given-names>T</given-names></name><article-title>Defensins: antimicrobial peptides of innate immunity</article-title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><issue>9</issue><fpage>710</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1038/nri1180</pub-id><pub-id pub-id-type="pmid">12949495</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Kai-Larsen</surname><given-names>Y</given-names></name><name><surname>Agerberth</surname><given-names>B</given-names></name><article-title>The role of the multifunctional peptide LL-37 in host defense</article-title><source>Front Biosci</source><year>2008</year><volume>13</volume><fpage>3760</fpage><lpage>3767</lpage><pub-id pub-id-type="pmid">18508470</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>PT</given-names></name><name><surname>Stenger</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wenzel</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>BH</given-names></name><name><surname>Krutzik</surname><given-names>SR</given-names></name><name><surname>Ochoa</surname><given-names>MT</given-names></name><name><surname>Schauber</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Meinken</surname><given-names>C</given-names></name><article-title>Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response</article-title><source>Science</source><year>2006</year><volume>311</volume><issue>5768</issue><fpage>1770</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1126/science.1123933</pub-id><pub-id pub-id-type="pmid">16497887</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>PT</given-names></name><name><surname>Stenger</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>DH</given-names></name><name><surname>Modlin</surname><given-names>RL</given-names></name><article-title>Cutting edge: vitamin D-mediated human antimicrobial activity against <italic>Mycobacterium tuberculosis</italic> is dependent on the induction of cathelicidin</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><issue>4</issue><fpage>2060</fpage><lpage>2063</lpage><pub-id pub-id-type="pmid">17675463</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Salahuddin</surname><given-names>N</given-names></name><name><surname>Ali</surname><given-names>F</given-names></name><name><surname>Hasan</surname><given-names>Z</given-names></name><name><surname>Rao</surname><given-names>N</given-names></name><name><surname>Aqeel</surname><given-names>M</given-names></name><name><surname>Mahmood</surname><given-names>F</given-names></name><article-title>Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT study [supplementary cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis</article-title><source>BMC Infect Dis</source><year>2013</year><volume>13</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-13-22</pub-id><pub-id pub-id-type="pmid">23331510</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Martineau</surname><given-names>AR</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Newton</surname><given-names>SM</given-names></name><name><surname>Kampmann</surname><given-names>B</given-names></name><name><surname>Hall</surname><given-names>BM</given-names></name><name><surname>Packe</surname><given-names>GE</given-names></name><name><surname>Davidson</surname><given-names>RN</given-names></name><name><surname>Eldridge</surname><given-names>SM</given-names></name><name><surname>Maunsell</surname><given-names>ZJ</given-names></name><article-title>A single dose of vitamin D enhances immunity to <italic>mycobacteria</italic></article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><issue>2</issue><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1164/rccm.200701-007OC</pub-id><pub-id pub-id-type="pmid">17463418</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Martineau</surname><given-names>AR</given-names></name><name><surname>Timms</surname><given-names>PM</given-names></name><name><surname>Bothamley</surname><given-names>GH</given-names></name><name><surname>Hanifa</surname><given-names>Y</given-names></name><name><surname>Islam</surname><given-names>K</given-names></name><name><surname>Claxton</surname><given-names>AP</given-names></name><name><surname>Packe</surname><given-names>GE</given-names></name><name><surname>Moore-Gillon</surname><given-names>JC</given-names></name><name><surname>Darmalingam</surname><given-names>M</given-names></name><name><surname>Davidson</surname><given-names>RN</given-names></name><article-title>High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial</article-title><source>Lancet</source><year>2011</year><volume>377</volume><issue>9761</issue><fpage>242</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61889-2</pub-id><pub-id pub-id-type="pmid">21215445</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Nnoaham</surname><given-names>KE</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><article-title>Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis</article-title><source>Int J Epidemiol</source><year>2008</year><volume>37</volume><issue>1</issue><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">18245055</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Raqib</surname><given-names>R</given-names></name><name><surname>Sarker</surname><given-names>P</given-names></name><name><surname>Bergman</surname><given-names>P</given-names></name><name><surname>Ara</surname><given-names>G</given-names></name><name><surname>Lindh</surname><given-names>M</given-names></name><name><surname>Sack</surname><given-names>DA</given-names></name><name><surname>Nasirul Islam</surname><given-names>KM</given-names></name><name><surname>Gudmundsson</surname><given-names>GH</given-names></name><name><surname>Andersson</surname><given-names>J</given-names></name><name><surname>Agerberth</surname><given-names>B</given-names></name><article-title>Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><issue>24</issue><fpage>9178</fpage><lpage>9183</lpage><pub-id pub-id-type="doi">10.1073/pnas.0602888103</pub-id><pub-id pub-id-type="pmid">16740661</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Islam</surname><given-names>D</given-names></name><name><surname>Bandholtz</surname><given-names>L</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Wigzell</surname><given-names>H</given-names></name><name><surname>Christensson</surname><given-names>B</given-names></name><name><surname>Agerberth</surname><given-names>B</given-names></name><name><surname>Gudmundsson</surname><given-names>G</given-names></name><article-title>Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><issue>2</issue><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1038/84627</pub-id><pub-id pub-id-type="pmid">11175848</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Bergman</surname><given-names>P</given-names></name><name><surname>Johansson</surname><given-names>L</given-names></name><name><surname>Asp</surname><given-names>V</given-names></name><name><surname>Plant</surname><given-names>L</given-names></name><name><surname>Gudmundsson</surname><given-names>GH</given-names></name><name><surname>Jonsson</surname><given-names>AB</given-names></name><name><surname>Agerberth</surname><given-names>B</given-names></name><article-title><italic>Neisseria gonorrhoeae</italic> downregulates expression of the human antimicrobial peptide LL-37</article-title><source>Cell Microbiol</source><year>2005</year><volume>7</volume><issue>7</issue><fpage>1009</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2005.00530.x</pub-id><pub-id pub-id-type="pmid">15953032</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Sarker</surname><given-names>P</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Tiash</surname><given-names>S</given-names></name><name><surname>Rekha</surname><given-names>RS</given-names></name><name><surname>Stromberg</surname><given-names>R</given-names></name><name><surname>Andersson</surname><given-names>J</given-names></name><name><surname>Bergman</surname><given-names>P</given-names></name><name><surname>Gudmundsson</surname><given-names>GH</given-names></name><name><surname>Agerberth</surname><given-names>B</given-names></name><name><surname>Raqib</surname><given-names>R</given-names></name><article-title>Phenylbutyrate counteracts <italic>Shigella</italic> mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>6</issue><fpage>e20637</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0020637</pub-id><pub-id pub-id-type="pmid">21673991</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Steinmann</surname><given-names>J</given-names></name><name><surname>Halldorsson</surname><given-names>S</given-names></name><name><surname>Agerberth</surname><given-names>B</given-names></name><name><surname>Gudmundsson</surname><given-names>GH</given-names></name><article-title>Phenylbutyrate induces antimicrobial peptide expression</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><issue>12</issue><fpage>5127</fpage><lpage>5133</lpage><pub-id pub-id-type="doi">10.1128/AAC.00818-09</pub-id><pub-id pub-id-type="pmid">19770273</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Yoshio</surname><given-names>H</given-names></name><name><surname>Tollin</surname><given-names>M</given-names></name><name><surname>Gudmundsson</surname><given-names>GH</given-names></name><name><surname>Lagercrantz</surname><given-names>H</given-names></name><name><surname>Jornvall</surname><given-names>H</given-names></name><name><surname>Marchini</surname><given-names>G</given-names></name><name><surname>Agerberth</surname><given-names>B</given-names></name><article-title>Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense</article-title><source>Pediatr Res</source><year>2003</year><volume>53</volume><issue>2</issue><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1203/00006450-200302000-00003</pub-id><pub-id pub-id-type="pmid">12538777</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Edfeldt</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>PT</given-names></name><name><surname>Chun</surname><given-names>R</given-names></name><name><surname>Fabri</surname><given-names>M</given-names></name><name><surname>Schenk</surname><given-names>M</given-names></name><name><surname>Wheelwright</surname><given-names>M</given-names></name><name><surname>Keegan</surname><given-names>C</given-names></name><name><surname>Krutzik</surname><given-names>SR</given-names></name><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Hewison</surname><given-names>M</given-names></name><article-title>T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><issue>52</issue><fpage>22593</fpage><lpage>22598</lpage><pub-id pub-id-type="doi">10.1073/pnas.1011624108</pub-id><pub-id pub-id-type="pmid">21149724</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Soliman</surname><given-names>MM</given-names></name><name><surname>Ahmed</surname><given-names>MM</given-names></name><name><surname>Salah-Eldin</surname><given-names>AE</given-names></name><name><surname>Abdel-Aal</surname><given-names>AA</given-names></name><article-title>Butyrate regulates leptin expression through different signaling pathways in adipocytes</article-title><source>J Vet Sci</source><year>2011</year><volume>12</volume><issue>4</issue><fpage>319</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.4142/jvs.2011.12.4.319</pub-id><pub-id pub-id-type="pmid">22122897</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>de Haan</surname><given-names>JB</given-names></name><name><surname>Gevers</surname><given-names>W</given-names></name><name><surname>Parker</surname><given-names>MI</given-names></name><article-title>Effects of sodium butyrate on the synthesis and methylation of DNA in normal cells and their transformed counterparts</article-title><source>Cancer Res</source><year>1986</year><volume>46</volume><issue>2</issue><fpage>713</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">2416432</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Soliman</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Yamaji</surname><given-names>D</given-names></name><name><surname>Matsushita</surname><given-names>Y</given-names></name><name><surname>Okamatsu-Ogura</surname><given-names>Y</given-names></name><name><surname>Makondo</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><article-title>Inverse regulation of leptin mRNA expression by short- and long-chain fatty acids in cultured bovine adipocytes</article-title><source>Domest Anim Endocrinol</source><year>2007</year><volume>33</volume><issue>4</issue><fpage>400</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.domaniend.2006.08.005</pub-id><pub-id pub-id-type="pmid">17011156</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Kin</surname><given-names>NW</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Stefanov</surname><given-names>EK</given-names></name><name><surname>Gallo</surname><given-names>RL</given-names></name><name><surname>Kearney</surname><given-names>JF</given-names></name><article-title>Cathelin-related antimicrobial peptide differentially regulates T- and B-cell function</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><issue>10</issue><fpage>3006</fpage><lpage>3016</lpage><pub-id pub-id-type="doi">10.1002/eji.201141606</pub-id><pub-id pub-id-type="pmid">21773974</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Agerberth</surname><given-names>B</given-names></name><name><surname>Charo</surname><given-names>J</given-names></name><name><surname>Werr</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>B</given-names></name><name><surname>Idali</surname><given-names>F</given-names></name><name><surname>Lindbom</surname><given-names>L</given-names></name><name><surname>Kiessling</surname><given-names>R</given-names></name><name><surname>Jornvall</surname><given-names>H</given-names></name><name><surname>Wigzell</surname><given-names>H</given-names></name><name><surname>Gudmundsson</surname><given-names>GH</given-names></name><article-title>The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations</article-title><source>Blood</source><year>2000</year><volume>96</volume><issue>9</issue><fpage>3086</fpage><lpage>3093</lpage><pub-id pub-id-type="pmid">11049988</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Ottenhoff</surname><given-names>TH</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name><article-title>Vaccines against tuberculosis: where are we and where do we need to go?</article-title><source>PLoS Pathog</source><year>2012</year><volume>8</volume><issue>5</issue><fpage>e1002607</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002607</pub-id><pub-id pub-id-type="pmid">22589713</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Campbell</surname><given-names>GR</given-names></name><name><surname>Spector</surname><given-names>SA</given-names></name><article-title>Autophagy induction by vitamin D inhibits both <italic>Mycobacterium tuberculosis</italic> and human immunodeficiency virus type 1</article-title><source>Autophagy</source><year>2012</year><volume>8</volume><issue>10</issue><fpage>1523</fpage><lpage>1525</lpage><pub-id pub-id-type="pmid">22892387</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Yuk</surname><given-names>JM</given-names></name><name><surname>Shin</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>HM</given-names></name><name><surname>Yang</surname><given-names>CS</given-names></name><name><surname>Jin</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>KK</given-names></name><name><surname>Lee</surname><given-names>ZW</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Jo</surname><given-names>EK</given-names></name><article-title>Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin</article-title><source>Cell Host Microbe</source><year>2009</year><volume>6</volume><issue>3</issue><fpage>231</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2009.08.004</pub-id><pub-id pub-id-type="pmid">19748465</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>GM</given-names></name><article-title>Effect of sodium butyrate on autophagy and apoptosis in Chinese hamster ovary cells</article-title><source>Biotechnol Prog</source><year>2012</year><volume>28</volume><issue>2</issue><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1002/btpr.1512</pub-id><pub-id pub-id-type="pmid">22492702</pub-id></mixed-citation></ref></ref-list></back></article>